We propose collaborative experiments that combine organic syntheses, X-ray crystallography, and computational chemistry, all aimed at developing an understanding of molecular structures as a basis for the development of antiviral therapies. We plan to test whether inhibiting influenza virus infection can be accomplished by blocking the binding of the virus to its cellular receptor and/or the inhibition of viral entry by blocking the virus's membrane fusion mechanism. We propose to use three-dimensional structure of the virus surface protein (HA) responsible for these activities (receptor binding and membrane fusion) and the structures of complexes of this protein with receptor analogs as a starting point for designing and testing inhibitors. We plan to develop computational methods and to determine other structures to assist the design process. We will explore increasing the affinity of ligands, matching bivalent ligands to the virus surface lattice, and interfering with necessary conformational changes by stabilizing the membrane-fusion-inactive conformation. Our goal is to develop a structural foundation for antiviral drug design.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM039589-10
Application #
5212135
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Verdine, Gregory L; Norman, Derek P G (2003) Covalent trapping of protein-DNA complexes. Annu Rev Biochem 72:337-66
Abdulaev, Najmoutin G; Strassmaier, Timothy T; Ngo, Tony et al. (2002) Grafting segments from the extracellular surface of CCR5 onto a bacteriorhodopsin transmembrane scaffold confers HIV-1 coreceptor activity. Structure 10:515-25
Lin, C H; Hare, B J; Wagner, G et al. (2001) A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies. Mol Cell 8:581-90
Mantis, N J; Kozlowski, P A; Mielcarz, D W et al. (2001) Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 19:3990-4001
Zhou, G; Ferrer, M; Chopra, R et al. (2000) The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg Med Chem 8:2219-27
Huang, H; Harrison, S C; Verdine, G L (2000) Trapping of a catalytic HIV reverse transcriptase*template:primer complex through a disulfide bond. Chem Biol 7:355-64
Ferrer, M; Harrison, S C (1999) Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol 73:5795-802
Frankel, A D; Young, J A (1998) HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67:1-25
Huang, H; Chopra, R; Verdine, G L et al. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-75
Weissenhorn, W; Calder, L J; Dessen, A et al. (1997) Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. Proc Natl Acad Sci U S A 94:6065-9

Showing the most recent 10 out of 39 publications